|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 38/44 | (2006.01) |
| G01N 33/53 | (2006.01) | ||
| G01N 33/68 | (2006.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61P 19/02 | (2006.01) |
| (11) | Number of the document | 3482768 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18214393.3 |
| Date of filing the European patent application | 2010-06-25 | |
| (97) | Date of publication of the European application | 2019-05-15 |
| (45) | Date of publication and mention of the grant of the patent | 2026-01-28 |
| (46) | Date of publication of the claims translation | 2026-04-27 |
| (30) | Number | Date | Country code |
| 26966909 P | 2009-06-25 | US | |
| 29871810 P | 2010-01-27 | US | |
| 24869809 P | 2009-10-05 | US |
| (72) |
ROSARIO-JANSEN, Theresa , US
WRIGHT, David, Erick , US
|
| (73) |
Horizon Therapeutics USA, Inc. ,
1 Horizon Way, Deerfield, Illinois 60015,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Būdai ir rinkiniai, skirti infuzijos reakcijos rizikai ir antikūnų sukeltam atsako praradimui užkirsti, stebint šlapimo rūgštį serume pegilintos urikazės terapijos metu |
| METHODS AND KITS FOR PREVENTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY |